Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2020-018
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Notice of Approval for Drug Clinical Trials
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
- Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
- Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Jianfeng Yien Biotechnology Co., Ltd. (hereinafter referred to as "Jianfeng Yien") , , a holding subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the company's holding subsidiary, received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, "JFAN-1001 Capsule, Notice No: 2020LP00246 " and "JFAN-1001 Capsules, Notification No: 2020LP00247 ". The relevant details are hereby announced as follows:
2. drug basic information content
drug name: JFAN-1001 capsule
English name: JFAN-1001Capsule
dosage form: capsule
application item: clinical research application
specification: 10mg , 30mg
registration classification: chemical drugs category
applicant: Zhejiang Jianfeng yien biotechnology co., ltd
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, 2020 6 February 7 accepted JFAN-1001 glue capsule meets the relevant requirements of drug registration and agrees to carry out clinical trials according to the submitted plan."
3. Drug Research and Development and Registration
JFAN-1001 is a new anti-tumor drug developed by Jianfeng Yien. The registration classification belongs to chemical drug 1 . Jianfeng Yien first submitted JFAN-1001 clinical trial application and was accepted on 2020 6 January 7 (acceptance numbers: CXHL2000255 , CXHL2000256 ). JFAN-1001 is a small molecule antineoplastic agent with indications for EGFR-T790M secondary mutation-positive locally advanced or metastatic non-squamous non-small cell lung cancer. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about 4676.04 .03 million yuan.
Market Situation of Similar Drugs in 4.
Currently, targeted drugs for epidermal growth factor receptor (EGFR ) inhibitors listed in China include: the first generation EGFR inhibitors include gefitinib, erlotinib and icotinib; The second generation EGFR inhibitors include afatinib and dacotinib; the third generation EGFR inhibitor includes AstraZeneca's osimertinib, which was approved for listing in the United States on November 11, 2009, , , , and approved for listing in China on March 122, , 2017, . AstraZeneca global annual sales of osimertinib in 2019, , .7 billion (source: 2019# AstraZeneca Annual Financial Statement for 129), almetinib of Jiangsu Haosen Pharmaceutical Co., Ltd. was approved to be listed in China in January , March this year. The company's JFAN-1001 is the third generation EGFR inhibitor with the same target as osimertinib, at present, similar drugs in the clinical research stage include efitinib of Shanghai Alex pharmaceutical technology co., ltd., avetinib of Hangzhou essen pharmaceutical research co., ltd., Nanjing shenghe pharmaceutical co., ltd. SH-1028 , Jiangsu osaikang pharmaceutical co., ltd. ASK120067 , Jiangsu runxin biotechnology co., ltd. RX518 and many other enterprises. Approval Procedure for 5. Products to Be Listed Jianfeng Yien will conduct clinical trials according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, production will be declared. Production and marketing can only be carried out after passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors August 19, 2020
More information
Daye Peak Won "Advanced Manufacturing Brand" in Huangshi City"
On the occasion of the fifth "China Brand Day", the office of Huangshi City Quality Strong City Working Committee held a grand awarding ceremony of "Promoting the High-quality Development of Huangshi 70 Brands", and Daye Jianfeng Cement Company was awarded the "Advanced Manufacturing Brand". In order to revitalize the post-epidemic economy and enhance the confidence of enterprises, Huangshi City Quality Strong City Working Committee Office organized and carried out a large-scale news investigation, publicity and exhibition activity of "Huangshi Glory, the era of glory-the 70th anniversary of the founding of the city, promoting the high-quality development of Huangshi 70 brands", aiming at vigorously publicizing the major achievements and advanced models of the high-quality development of various industries in Huangshi and the construction of strong quality strong quality city, and encouraging enterprises, and leading enterprises to further establish the strong quality, help Yellowstone "five city construction", cohesion of economic and social high-quality development of a strong force. After the public vote, the 70 brands and 30 characteristic brands selected to promote the high-quality development of Huangshi in the 70 years since the establishment of the city were awarded the advanced manufacturing brand, modern service brand, high-quality education brand, excellent cultural brand, modern agricultural brand and Huangshi high-quality development characteristic brand respectively. Daye Peak won the honor of "advanced manufacturing brand.
2021
05-21
Learning Party History, Strong Faith
On April 29, the staff of the peak building stopped to browse when they passed the newly created party history knowledge propaganda wall. 2021 is the 100 anniversary of the founding of the Communist Party of China, the Central Committee called on the whole party to carry out the study and education of party history. Since the party committee of the group company deployed the party history study and education work, party organizations at all levels of the company have taken active actions to further strengthen their ideals and beliefs through various forms such as special party classes, concentrated study, visiting the red education base, and reviewing the oath of joining the party.
2021
05-06
Cement industry, Huangshi City two honors flower daye peak
In April, China's cement industry and Huangshi City in Hubei Province each won an honor by Daye Peak, and the company's work in environmental protection and poverty alleviation was affirmed. The 2021 China Cement Industry Summit held in Hangzhou from April 20 to 21, with the theme of "common mission, innovation and common development", discussed the current development trend of the cement industry in depth. During the meeting, a series of awards for the top 100 cement industry were held. After reviewing multi-dimensional information such as brand growth, brand productivity, brand awareness and brand reputation, daye peak was awarded the title of "enterprise with outstanding contribution to environmental protection. Recently, Huangshi City Federation of Industry and Commerce (Chamber of Commerce) held the 6th Executive Committee of the 12th session to review the work in 2020 and deploy the targets and tasks for 2021. It commended the city's advanced collective of "precise poverty alleviation and private enterprise assistance". Daye Peak was awarded the honorary title of "Advanced Private Enterprise.
2021
05-06
Yang Zhi, head of Huangping County, Guizhou Province, visited Jianfeng
On April 16, a delegation led by Yang Zhi, head of Huangping County, Guizhou Province, visited the headquarters of the group company and held discussions with the group leaders on the future development of Huangping peak and further strengthening the in-depth cooperation between the two sides. During the exchange, Chairman Jiang Xiaomeng introduced the development of Jianfeng in recent years, which aroused unanimous praise from the members of the delegation. Yang Zhi said that Jianfeng is an enterprise with a sense of social responsibility and serious business. He hopes to further cooperate in other industrial fields to promote the economic development of Huangping.
2021
04-21
The Pursuit and Dream of the Spike of "Egoist" of "Lie to the People"
On March 23, China Cement Network published an exclusive interview with Jiang Xiaomeng, chairman of the group company, under the title of "the pursuit and Dream of the peak of self-interest. During the interview, Jiang Xiaomeng expressed his views on the future development trend of China's cement industry and introduced the development ideas of the peak cement industry in the future. The full text of this article is reproduced here...
2021
04-12
Daye Peak Won the Title of "Charity Enterprise" in Daye City
Daye city recently organized the 2020 Metallurgical Conference to review and summarize the 2020 Metallurgical Work and arrange the deployment of 2021. Wang Gang, secretary of the Daye Municipal Party Committee, attended the conference and made an important speech, in particular, he expressed his heartfelt thanks to a group of enterprises and entrepreneurs, such as Jinpai Company and Daye Peak, for coming forward, giving generously and helping at the most critical juncture of Daye epidemic prevention and control. The conference announced the "Decision of Daye Municipal Party Committee and Municipal Government on Releasing the 2020 Charity Contribution List" and commended it on the spot. Daye Peak and other enterprises were awarded the honorary title of "2020 Charity Enterprise. Zhang Fengliang, deputy general manager of the group company and general manager of Daye Peak, accepted the commendation on behalf of Daye Peak and delivered a keynote speech at the meeting as a representative of the commended enterprise. (Daye Peak)
2021
04-12